**Table 1** Clinicopathological features of PANDEMIC-Group

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **#** | **Sex** | **Age** | **Date of surgery** | **Disease group** | **Pathology** | **Stage** | **Type of surgery** | **SARS-Cov-2 test** | **HT (days)** | **FU  (days)** | **Complications** |
| 1 | F | 87 | Feb-24 | Malignant | Nasal BSC | yr pT1N0M0 | Rhinectomy revision + ER | n.p. | 6 | 71 | - |
| 2 | M | 89 | Feb-25 | Epistaxis | Left epistaxis | - | Cauterization | n.p. | 5 | 70 | - |
| 3 | F | 82 | Feb-26 | Inflammatory | Invasive mycosis | - | FESS | n.p. | 5 | 69 | - |
| 4 | M | 50 | Feb-28 | Benign | Inverted papilloma | - | ER | n.p. | 3 | 67 | - |
| 5 | M | 53 | Mar-2 | Malignant | Nasopharyngeal ACC | yr pT4bN0M0 | NER III | n.p. | 10 | 64 | - |
| 6 | M | 63 | Mar-2 | Malignant | Sphenoidal mts from  prostatic ADC | - | Endoscopic endonasal biopsy | n.p. | 4 | 64 | - |
| 7 | M | 51 | Mar-3 | Benign | Inverted papilloma | - | ER (PLA) | n.p. | 3 | 63 | - |
| 8 | M | 73 | Mar-3 | Benign | Inverted papilloma | - | ER | n.p. | 6 | 63 | - |
| 9 | F | 13 | Mar-4 | Benign | Frontal-orbital dysplasia | - | ER | n.p. | 4 | 62 | - |
| 10 | M | 62 | Mar-5 | Benign | Intraconal hemangioma | - | ER | n.p. | 7 | 61 | - |
| 11 | M | 12 | Mar-5 | Inflammatory | Orbital abscess | - | Drainage (superior eyelid approach) | n.p. | 6 | 61 | - |
| 12 | M | 65 | Mar-6 | Malignant | Maxillary SCC | pT3N0M0 | Endoscopic assisted radical maxillectomy | n.p. | 32 | 60 | - |
| 13 | F | 59 | Mar-9 | Functional | Severe bilateral Graves ophthalmopathy | - | Orbital decompression (combined superior eyelid-transnasal approach) | n.p. | 10 | 57 | - |
| 14 | F | 49 | Mar-11 | Malignant | Chondrosarcoma | pT4bN0M0 | Endoscopic endonasal debulking | n.p. | 3 | 55 | Brain abscess |
| 15 | M | 70 | Mar-13 | Malignant | Sinonasal ITAC | pT2N0M0 | ERTC | n.p. | 9 | 53 | - |
| 16 | M | 75 | Mar-19 | Malignant | Maxillary ACC relapse | yr pT3N2aM0 | Radical maxillectomy + mRND | n.p. | 31 | 47 | - |
| 17 | F | 46 | Mar-25 | CSFL | Left olfactory cleft meningocele | - | Skull base reconstruction | ⧿ | 9 | 41 | - |
| 18 | M | 36 | Apr-2 | Malignant | Sinonasal SCC in IP | pT2N0M0 | ER | ⧾ | 24 | 33 | - |
| 19 | F | 83 | Apr-6 | Epistaxis | Left epistaxis | - | Cauterization | ⧿ | 6 | 29 | - |
| 20 | M | 63 | Apr-6 | Malignant | Sinonasal hemangiopericytoma | pT4aN0M0 | ER | ⧿ | 6 | 29 | - |
| 21 | M | 71 | Apr-9 | Malignant | Left maxillary SCC | pT3N0M0 | Endoscopic assisted radical maxillectomy | ⧿ | 18 | 26 | - |
| 22 | F | 80 | Apr-14 | Malignant | Sinonasal NEC | yr pT4aN3bM0 | ER, OE, mRND | ⧿ | 18 | 21 | - |
| 23 | F | 47 | Apr-15 | Inflammatory | Frontal sinus prosthesis superinfection | - | Drainage (frontal osteoplasty approach) | ⧿ | 11 | 20 | - |
| 24 | M | 39 | Apr-21 | CSFL | Right olfactory cleft CSFL | - | Skull base reconstruction | ⧿ | 10 | 14 | - |
|  | **Abbreviations**: ACC, adenoid cystic carcinoma; ADC, adenocarcinoma; BSC, basal cell carcinoma; CSFL, cerebrospinal fluid leak; ER, endoscopic resection; ERTC, endoscopic resection with transnasal craniectomy; FESS, functional endoscopic surgery; FU, follow-up; HT, hospitalization time; IP, inverted papilloma; ITAC, intestinal-type adenocarcinoma; mRND, modified radical neck dissection (levels I-V); NEC, neuroendocrine carcinoma; OE, orbital exenteration; PLA, prelacrimal approach; SCC, squamous cell carcinoma. | | | | | | | | | | |

**Table 2** Statistical comparison between PANDEMIC-Group and CONTROL-Group according to age, gender, patients’ geographic origin, mean hospitalization time and postoperative stay

|  |  |  |  |
| --- | --- | --- | --- |
| **Demographic and clinical data** | **PANDEMIC-Group** Feb-Apr, 2020 | **CONTROL-Group** Feb-Apr, 2019 | **p value** |
| Age | 59 ± 20 years | 53 ± 17 years | 0.182 |
| Gender (males percentage) | 62.5% | 47.5% | 0.209 |
| Geographic origin (extra-regional patients percentage) | 41.7% | 39.3% | 0.844 |
| Hospitalization time (days) | 6.77 ± 5.23 | 10.02 ± 11.6 | 0.119 |
| Postoperative stay (days) | 5.98 ± 5.12 | 7.76 ± 10.9 | 0.924 |

**Table 3** Distribution of cases according to the pathology treated in PANDEMIC-Group and CONTROL-Group

|  |  |  |
| --- | --- | --- |
| **Pathologies treated** | **PANDEMIC-Group** Feb-Apr, 2020 | **CONTROL-Group** Feb-Apr, 2019 |
| Benign tumors | 5 (20.8%) | 12 (19.7%) |
| Cerebrospinal fluid leak | 2 (8.3%) | 2 (3.3%) |
| Epistaxis | 2 (8.3%) | 3 (4.9%) |
| Functional diseases | 1 (4.2%) | 5 (8.2%) |
| Inflammatory diseases | 3 (12.5%) | 28 (45.9%) |
| Malignant tumors | 11 (45.8%) | 11 (18.0%) |
| **Total** | **24 (100.0%)** | **61 (100.0%)** |

**Table 4** Medical staff survey. Data regarding contact, PPE use and diagnostic tests performed

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Survey item** | | **Attendings** | **Residents** | | **Total** |
| ***Contact with COVID-19 positive patient*** | | 10 | 2 | | 12/26 |
|  | *February 24th - March 22nd* | 10 | 2 | | 12 |
|  | *March 23rd - April 24th* | 0 | 0 | | 0 |
| ***Contact with COVID-19 positive patient*** | | 11 | 9 | | 20/26 |
|  | *Surgical activity* | 0 | 2 | | 2 |
|  | *Tracheotomy in COVID-19 patients* | 5 | 1 | | 6 |
|  | *Ward activity* | 6 | 6 | | 12 |
| ***Lack of PPE during COVID-19 contact*** | | 4 | 2 | | 6/26 |
|  | *Not recommended* | 2 | 0 | | 2 |
|  | *No availability* | 1 | 1 | | 2 |
|  | *Patient’s COVID-19 status not tested* | 1 | 1 | | 2 |
| ***Nasopharyngeal swabs*** | | 1 | 0 | | 1/26 |
|  | *Positive* | 0 | 0 | | 0 |
|  | *Negative* | 1 | 0 | | 1 |
| ***Rapid test*** | | 7 | 0 | | 7/26 |
|  | *Positive* | 1\* | 0 | | 1\* |
|  | *Negative* | 6 | 0 | | 6 |
| *\* Rapid test result: positive for IgG* | | | |  | |